News | News By Subject | News by Disease News By Date | Search News

Hepatitis (misc) News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it     11/2/2016
Bay Area's Tobira Strikes a $74.5 Million Evogliptin and Cenicriviroc Deal with Dong-A ST     4/11/2016
AbbVie (ABBV)’s Viekira Pak Clears Another Hurdle, 100% HCV-1b Clearance Rate in Phase III Trial     6/25/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Vertex Pharmaceuticals (MA) (VRTX) Tanks as FDA Puts Hold on Hep C Trial     7/30/2013
India Rejects Bayer AG (BAY.F) Plea Against Cheap Cancer Drug     3/5/2013
FDA Sees Safety Issue with Merck & Co., Inc. (MRK) Hepatitis Drug     4/25/2011
FDA Asks for More Data on Dynavax Technologies Corporation (DVAX)'s Hepatitis Vaccine     2/9/2009
Maxygen, Inc. (MAXY) and Roche (RHHBY) Terminate Development of Hepatitis Drug     11/26/2007
Enzon Pharmaceuticals, Inc. (ENZN) Sells 25 Percent Interest in Hepatitis C Drug     8/20/2007
Schering-Plough Corporation (SGP) Release: European Union's CHMP Adopts Positive Opinion For Shorter Course Of PEGINTRON(R) And REBETOL(R) Combination Therapy For Certain Hepatitis C Patients With Genotype 1 And Low Viral Load     7/29/2005
Valeant Pharmaceuticals International (VRX) Reports Positive Data From Pradefovir Mesylate Phase 2 Study; Results From 24-Week Interim Period Show Significant Decline In HBV Viral Load With No Evidence Of Nephrotoxicity     7/19/2005
Avexa Limited (AVX.AX) Back To The Drawing Board On Hepatitis B Program     6/30/2005

News from Around the Web
The Lab Breakthrough And The Two Men Behind Today’s Pricey Hepatitis C Cures     9/13/2016
Hospital Warns 213 Patients May Have Been Exposed To Hepatitis, HIV Due To Tampering of Drugs By Ex-Employee     2/26/2016
Diagnostics Hepatitis E Assay, Hannover Medical School Study     2/26/2016
Teen Girl Develops Hepatitis After Drinking Green Tea Bought Online     9/28/2015
Hepatitis Pills Spark Biggest Jump In Drug Costs In A Decade     3/11/2015
BioSpace’s Favorite FDA Tricks Or Treats     10/24/2014
US, EU Grant Accelerated Reviews Of Merck & Co., Inc. (MRK) Hepatitis Drug     1/7/2011
Roche Holding AG (RHHBF.PK), Johnson & Johnson (JNJ) and Biogen Idec, Inc. (Massachusetts) (BIIB) Prodded by FDA for More Neglected Disease Medicines     6/18/2010
University of Cincinnati Medical Center HEALTH LINE: New Drugs May Halt Rise In Hepatitis     5/22/2007
Liver Regeneration may be Simpler than Previously Thought     4/12/2007
Colitis Patients Need Better Immunization: Report     8/31/2006
Blood Test May Curb Liver Damage From TB Drug     7/26/2005
Potatoes Deliver Hepatitis Vaccine In Human Trials     2/15/2005
Tomato Vaccine     10/11/2004
FDA: Glaxo Vaccine Information Wrong     7/14/2004

Press Releases
Prime Therapeutics Study Finds 97 Percent Of Hepatitis C Patients Cured With Harvoni Treatment     3/21/2017
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders     3/14/2017
MRC Technology Licenses Antibody To Shanghai Newsummit Biopharma Group Co., Ltd For Development Of Hepatitis C Virus Infection Therapeutic     3/14/2017
Enanta Pharmaceuticals, Inc. Announces Japanese Ministry Of Health, Labour And Welfare Grants Priority Review For AbbVie (ABBV)’s Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C     3/14/2017
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders     3/8/2017
Trio Health Reports Rapid Increase In Non-Start Rates For Hepatitis C Treatment Predominantly Due To Coverage Denials     3/8/2017
Enanta Pharmaceuticals, Inc. Announces U.S. FDA Grants Priority Review To AbbVie (ABBV)’s Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)     2/2/2017
Gilead (GILD) Release: EMA Validates Company’s Marketing Authorization Application For Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)     1/20/2017
European Commission (EC) Grants Marketing Authorization For Gilead (GILD)’s Vemlidy (Tenofovir Alafenamide, TAF) For The Treatment Of Chronic Hepatitis B Virus Infection     1/11/2017
CFDA Accepts NDA For Hepatitis C Drug From Ascletis     12/29/2016
Benitec (BLT.AX) Announces Positive Data For Its Hepatitis B Virus Program     12/20/2016
AiCuris Announces U.S. NIH Support Of Preclinical Study With AIC649 Against Chronic Hepatitis B     11/23/2016
Eiger Biopharma Announces Additional LOWR HDV Program Data, Clinical And Regulatory Plans At The American Association for Study of Liver Diseases Meeting     11/15/2016
Merck & Co. (MRK) Announces Findings For Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates Of Sustained Virologic Response In People With Genotypes 1, 2 Or 3 Infection     11/14/2016
Arrowhead Pharma (ARWR) And Spring Bank Pharmaceuticals, Inc. Announce Clinical Collaboration For ARC-520 And SB 9200 In Chronic Hepatitis B     10/6/2016